Evidence map›Paper›PMID 42284622›Full record

Trial reportESMO open2026

Avelumab first-line maintenance for advanced urothelial carcinoma: long-term outcomes from the JAVELIN Bladder 100 trial in patients with high body mass index or diabetes mellitus.

J B Aragon-Ching, S Gupta, P Grivas, S H Park, D P Petrylak, S S Sridhar, H Gurney, N Jacob, K Tyroller, J Hoffman and 1 more

Abstract readRandomized Controlled TrialClinical Trial, Phase III
PubMed Full text at PMC Publisher
In one paragraph

Trial report in ESMO open, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

J B Aragon-ChingInova Schar Cancer Institute, Fairfax, USA. Electronic address: jeanny.aragon-ching@inova.org.
S GuptaTaussig Cancer Institute, Cleveland Clinic Foundation, Cleveland, USA.
P GrivasUniversity of Washington, Fred Hutch Cancer Center, Seattle, USA.
S H ParkSamsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.
D P PetrylakYale School of Medicine, New Haven, USA.
S S SridharPrincess Margaret Cancer Centre, University Health Network, Toronto, Canada.
H GurneyDepartment of Clinical Medicine, Macquarie University, Sydney, Australia.
N JacobMerck Healthcare KGaA, Darmstadt, Germany.
K TyrollerEMD Serono Research & Development Institute, Inc., Billerica, MA, USA, an affiliate of Merck KGaA.
J HoffmanEMD Serono Research & Development Institute, Inc., Billerica, MA, USA, an affiliate of Merck KGaA.
J BellmuntDepartment of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundAvelumab first-line maintenance is the recommended treatment option for patients with advanced urothelial carcinoma (UC) without progression following platinum-based chemotherapy (PBC), based on the phase III JAVELIN Bladder 100 trial. High body mass index (BMI; ≥30 kg/m PATIENTS AND

methodsJAVELIN Bladder 100 enrolled patients with advanced UC without progression after first-line PBC, who were randomly assigned to receive avelumab plus best supportive care (BSC; n = 350) or BSC alone (n = 350). The primary endpoint was overall survival (OS) from the time of random assignment.

resultsOverall, 122 patients (17.4%) had high BMI and 114 (16.3%) had DM. After a median follow-up of ≥38 months in both arms, hazard ratios for OS with avelumab plus BSC versus BSC alone were 0.77 [95% confidence interval (CI) 0.49-1.21] in patients with high BMI and 0.60 (95% CI, 0.37-0.95) in patients with DM. Long-term safety of avelumab maintenance in these subgroups was generally consistent with that of the overall population.

conclusionsExploratory analyses support the use of avelumab first-line maintenance in patients with advanced UC without progression following PBC, including those with high BMI or DM.

Indexed as

Antibodies, Monoclonal, HumanizedAntineoplastic Agents, ImmunologicalCarcinoma, Transitional CellDiabetes MellitusUrinary Bladder NeoplasmsAgedBody Mass IndexFemaleHumansMaleMiddle AgedAntibodies, Monoclonal, HumanizedAntineoplastic Agents, Immunologicalavelumabavelumabbladder cancerdiabetes mellitushigh body mass indexmaintenance therapyurothelial carcinoma

Identifiers

PMID42284622
PMCPMC13279007

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.